Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Assetmark Inc.

Assetmark Inc. raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 27.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,667 shares of the medical equipment provider’s stock after purchasing an additional 1,437 shares during the quarter. Assetmark Inc.’s holdings in Hologic were worth $543,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its position in Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the period. Swedbank AB bought a new stake in shares of Hologic in the 1st quarter worth $120,827,000. Black Creek Investment Management Inc. raised its stake in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after buying an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Hologic by 1,023.3% in the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after buying an additional 815,960 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Hologic in the 2nd quarter worth $39,427,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HOLX. Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday. Leerink Partners reduced their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Stephens reissued an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Royal Bank of Canada upped their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $78.60 on Friday. The company’s 50 day simple moving average is $80.71 and its 200 day simple moving average is $78.23. The stock has a market capitalization of $18.26 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 2.50 and a beta of 0.98. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the business earned $0.89 earnings per share. Hologic’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, research analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.